MMP3 and arthritic joint disease: These findings demonstrated that concomitantly administered etanercept and tacrolimus exerted additive and/or synergistic inhibitory effects on the progression of arthritis, largely via suppression of MMP-3 production, CD11bhigh OCP mobilization, and osteoclast differentiation but did not affect ADA production.